Liver cirrhosis is a major cause of death worldwide. According to the report of Global Burden of Disease Study 2013, the number of all age deaths from liver cirrhosis has increased by 45.6% between 1993 and 2013 (from 838.0 thousand in 1993 to 1221.1 thousand in 2013). Liver cirrhosis is the 13th cause of global years of life lost in 2013. Lots of novel therapies for liver cirrhosis and its complications have been greatly evolved during the past decades. However, liver transplantation remains the sole curative treatment option. Given a dismal prognosis of liver cirrhosis, it is very important for clinicians and patients to understand the potential risk factors for early death and the therapeutic algorithms.

We invite the researchers to contribute original research articles and review articles to explore the prognostic assessment and management of liver cirrhosis. We are particularly interested in high-quality systematic reviews and meta-analyses in this field.

Potential topics include but are not limited to the following:

• Short- and long-term follow-up outcomes of liver cirrhosis
• Novel biomarkers or mathematical models for assessing the short- and long-term survival of liver cirrhosis
• Novel stages of liver cirrhosis
• Role of nutritional status, portal haemodynamic status, cardiac function, and renal function for the prognostic assessment of liver cirrhosis
• Impact of therapeutic options on the prognosis of liver cirrhosis, such as direct antiviral drugs, statins, anticoagulants, nonselective beta-blockers in ascites, early use of transjugular intrahepatic portosystemic shunt in high-risk variceal bleeding, endoscopic treatment of variceal bleeding, and so forth
• Impact of portal vein thrombosis on the prognosis of liver cirrhosis
• Management of upper gastrointestinal bleeding, ascites, hepatic encephalopathy, hepatic hydrothorax, hypersplenism, hepatic myelopathy, and portal vein thrombosis in liver cirrhosis